Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Structure Therapeutics Inc (GPCR)

Structure Therapeutics Inc (GPCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,873,007
  • Shares Outstanding, K 57,261
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,620 K
  • EBIT $ -142 M
  • EBITDA $ -148 M
  • 60-Month Beta -3.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.09

Options Overview Details

View History
  • Implied Volatility 82.25% ( +2.15%)
  • Historical Volatility 58.57%
  • IV Percentile 64%
  • IV Rank 14.46%
  • IV High 224.41% on 05/31/24
  • IV Low 58.22% on 08/23/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 222
  • Volume Avg (30-Day) 589
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 21,066
  • Open Int (30-Day) 17,200

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.22
  • Number of Estimates 5
  • High Estimate -0.10
  • Low Estimate -0.31
  • Prior Year -0.17
  • Growth Rate Est. (year over year) -29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.48 +7.53%
on 11/18/24
42.57 -25.53%
on 10/31/24
-7.12 (-18.34%)
since 10/21/24
3-Month
29.48 +7.53%
on 11/18/24
45.37 -30.13%
on 09/23/24
-7.94 (-20.03%)
since 08/21/24
52-Week
26.61 +19.13%
on 12/18/23
66.38 -52.24%
on 12/04/23
-19.63 (-38.24%)
since 11/21/23

Most Recent Stories

More News
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

GPCR : 31.45 (-3.85%)
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

GPCR : 31.45 (-3.85%)
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

GPCR : 31.45 (-3.85%)
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024 

GPCR : 31.45 (-3.85%)
Can Roche Challenge Lilly and Novo in the Weight Loss Market?

One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.

NVO : 102.24 (-2.88%)
LLY : 744.73 (-1.15%)
GPCR : 31.45 (-3.85%)
RHHBY : 35.3800 (+0.71%)
This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

NVO : 102.24 (-2.88%)
MS : 134.44 (+2.09%)
LLY : 744.73 (-1.15%)
GPCR : 31.45 (-3.85%)
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?

NVO : 102.24 (-2.88%)
LLY : 744.73 (-1.15%)
GPCR : 31.45 (-3.85%)
SNY : 47.65 (-0.27%)
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.

LLY : 744.73 (-1.15%)
VKTX : 53.29 (+3.42%)
GPCR : 31.45 (-3.85%)
Could Structure Therapeutics Become the Next Novo Nordisk?

Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.

GPCR : 31.45 (-3.85%)
NVO : 102.24 (-2.88%)
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?

Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.

GPCR : 31.45 (-3.85%)
NVO : 102.24 (-2.88%)
LLY : 744.73 (-1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc. is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 34.38
2nd Resistance Point 33.78
1st Resistance Point 33.24
Last Price 31.45
1st Support Level 32.11
2nd Support Level 31.51
3rd Support Level 30.97

See More

52-Week High 66.38
Fibonacci 61.8% 51.19
Fibonacci 50% 46.49
Fibonacci 38.2% 41.80
Last Price 31.45
52-Week Low 26.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar